ATE444358T1 - Tumor gezielter vektor - Google Patents

Tumor gezielter vektor

Info

Publication number
ATE444358T1
ATE444358T1 AT98925827T AT98925827T ATE444358T1 AT E444358 T1 ATE444358 T1 AT E444358T1 AT 98925827 T AT98925827 T AT 98925827T AT 98925827 T AT98925827 T AT 98925827T AT E444358 T1 ATE444358 T1 AT E444358T1
Authority
AT
Austria
Prior art keywords
tumor targeted
targeted vector
vector
noi
poi
Prior art date
Application number
AT98925827T
Other languages
English (en)
Inventor
Susan Kingsman
Christopher Bebbington
Fiona Ellard
Miles Carroll
Kevin Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE444358(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9711579.4A external-priority patent/GB9711579D0/en
Priority claimed from GBGB9713150.2A external-priority patent/GB9713150D0/en
Priority claimed from GBGB9714230.1A external-priority patent/GB9714230D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE444358T1 publication Critical patent/ATE444358T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT98925827T 1997-06-04 1998-06-04 Tumor gezielter vektor ATE444358T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711579.4A GB9711579D0 (en) 1997-06-04 1997-06-04 Therapeutic genes
GBGB9713150.2A GB9713150D0 (en) 1997-06-20 1997-06-20 Fusion proteins
GBGB9714230.1A GB9714230D0 (en) 1997-07-04 1997-07-04 Therapeutic genes
PCT/GB1998/001627 WO1998055607A2 (en) 1997-06-04 1998-06-04 Tumor targeted vector

Publications (1)

Publication Number Publication Date
ATE444358T1 true ATE444358T1 (de) 2009-10-15

Family

ID=27268875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925827T ATE444358T1 (de) 1997-06-04 1998-06-04 Tumor gezielter vektor

Country Status (16)

Country Link
US (6) US6852703B1 (de)
EP (2) EP1717248A1 (de)
JP (3) JP2002507117A (de)
CN (1) CN1224712C (de)
AT (1) ATE444358T1 (de)
AU (1) AU747602B2 (de)
CA (1) CA2292760A1 (de)
CY (1) CY1109686T1 (de)
DE (1) DE69841204D1 (de)
DK (1) DK1012259T3 (de)
ES (1) ES2332435T3 (de)
IL (1) IL132596A0 (de)
NO (1) NO995901L (de)
NZ (1) NZ500633A (de)
PT (1) PT1012259E (de)
WO (1) WO1998055607A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
AU747602B2 (en) 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
KR20020049054A (ko) * 1999-11-18 2002-06-24 찰스 굿맨 항체
CN1423660A (zh) * 1999-11-18 2003-06-11 牛津生物医学（英国）有限公司 抗体
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003012054A2 (en) * 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7939059B2 (en) * 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
EP1629008A1 (de) 2003-05-21 2006-03-01 Ares Trading S.A. Tnf-ähnliches sekretiertes protein
EP1621550A1 (de) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-ansteuernde Zellen, welche "tumor necrosis factor-related apoptosis inducing ligand" (TRAIL) exprimieren
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20060088522A1 (en) * 2004-09-10 2006-04-27 Wyeth Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
NZ596295A (en) 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
ES2378407T3 (es) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
MX2009003542A (es) * 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
WO2010007365A1 (en) * 2008-07-15 2010-01-21 Oxford Biomedica (Uk) Ltd Immunotherapeutic method
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) * 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
US9265969B2 (en) * 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
RU2646498C2 (ru) 2012-01-24 2018-03-05 Пфайзер Инк. Способы детектирования 5Т4-положительных циркулирующих опухолевых клеток и способы диагностики 5Т4-положительного рака у млекопитающего
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP4059521A1 (de) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur diagnose und behandlung von tumoren
EP3215522B1 (de) 2014-11-03 2021-12-01 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Gegen bob1 gerichtete t-zell-rezeptoren und verwendungen davon
WO2016142783A2 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP4137150A1 (de) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
AU2018235130B2 (en) 2017-03-15 2023-12-07 Oxford Biomedica (Uk) Limited Method
CA3059882A1 (en) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
WO2019173417A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-tip-1 antibodies and uses thereof
CR20250347A (es) 2018-03-12 2025-09-23 Genmab As ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463)
WO2021129656A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
DE68923027D1 (de) * 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JPH04500308A (ja) 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (de) 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5439654A (en) 1994-03-10 1995-08-08 Steris Corporation Cutter for opening sterilant reagent cups
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
ES2167391T3 (es) 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
DE69634606D1 (de) 1995-10-16 2005-05-19 Dana Farber Cancer Inst Inc Neue expressionsvektoren und verfahren zu deren verwendung
WO1997017090A1 (en) * 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
DE19724502C1 (de) 1997-06-11 1998-10-08 Webasto Thermosysteme Gmbh Heizgerät
CA2338982C (en) 1998-08-10 2011-03-15 Urogenesys, Inc. Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
CN1423660A (zh) 1999-11-18 2003-06-11 牛津生物医学（英国）有限公司 抗体
KR20020049054A (ko) 1999-11-18 2002-06-24 찰스 굿맨 항체

Also Published As

Publication number Publication date
NO995901L (no) 2000-02-04
US20090017532A1 (en) 2009-01-15
US7531648B2 (en) 2009-05-12
AU7780198A (en) 1998-12-21
JP2011000122A (ja) 2011-01-06
NZ500633A (en) 2002-10-25
US20110065173A1 (en) 2011-03-17
DE69841204D1 (de) 2009-11-12
CN1258319A (zh) 2000-06-28
DK1012259T3 (da) 2010-01-18
NO995901D0 (no) 1999-12-02
US20060286634A1 (en) 2006-12-21
US20030018004A1 (en) 2003-01-23
US6852703B1 (en) 2005-02-08
ES2332435T3 (es) 2010-02-04
JP2009153524A (ja) 2009-07-16
PT1012259E (pt) 2009-11-06
IL132596A0 (en) 2001-03-19
EP1717248A1 (de) 2006-11-02
CY1109686T1 (el) 2014-08-13
EP1012259A2 (de) 2000-06-28
US20050032216A1 (en) 2005-02-10
EP1012259B1 (de) 2009-09-30
US8084249B2 (en) 2011-12-27
WO1998055607A2 (en) 1998-12-10
WO1998055607A3 (en) 1999-03-04
CN1224712C (zh) 2005-10-26
JP2002507117A (ja) 2002-03-05
AU747602B2 (en) 2002-05-16
US7718627B2 (en) 2010-05-18
CA2292760A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
DE69841204D1 (de) Tumor gezielter Vektor
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
PL309403A1 (en) Modified cutinases, dna, vector and host
GB9223816D0 (en) Heat shock proteins and the treatment of tumours
DE69940785D1 (de) Proteinexpressionsvektor und benutzung desselbigen
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
ATE262038T1 (de) Br96 mutantantikörper die mit menschlichen karzinomen reagieren
EP0237045A3 (en) Dna encoding flagellin and vector having the same
GR930300141T1 (en) Taxane derivatives, their preparation and use in oncology
NZ237198A (en) Zymogen form of protein c, dna, vector and use as a pharmaceutical
NZ292565A (en) Production of stabilised complement protein-3 convertase
HU9501771D0 (en) Modified cutinases, dna, vector and host
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
EP0273800A3 (en) Hirudine variants, their use and preparation
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
AU109615S (en) Ground engaging element
AU4884001A (en) Novel collectins
EP0647138A4 (de) Polypeptide erhältlich aus fasciola spezien, und vakzine, therapieverfahren und dna sequenzen diese peptide kodierend.
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
ZA93211B (en) Enzyme castration of animals and tumor treatment.
Lambert Endoscopic therapy of esophago-gastric tumors
Conio Endoscopic features of Barrett's esophagus
GB9604518D0 (en) Novel compounds
JPS5519244A (en) Anti-malignant tumor agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012259

Country of ref document: EP